ZC3H7A antibody - middle region (ARP31904_P050)
- Known as:
- ZC3H7A (anti-) - middle region (ARP31904_P050)
- Catalog number:
- arp31904_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- ZC3H7A antibody - middle region (ARP31904_P050)
Related genes to: ZC3H7A antibody - middle region (ARP31904_P050)
- Gene:
- ZC3H7A NIH gene
- Name:
- zinc finger CCCH-type containing 7A
- Previous symbol:
- ZC3HDC7, ZC3H7
- Synonyms:
- HSPC055, FLJ20318
- Chromosome:
- 16p13.13
- Locus Type:
- gene with protein product
- Date approved:
- 2004-04-22
- Date modifiied:
- 2016-10-05
Related products to: ZC3H7A antibody - middle region (ARP31904_P050)
Related articles to: ZC3H7A antibody - middle region (ARP31904_P050)
- Huangkui capsule (HKC), a Chinese herbal medicine derived from (L.) ethanol extract, has clinical efficacy against diabetic nephropathy (DN). Our research group has actively engaged in exploring the efficacy of HKC in treating DN. The underlying pharmacological mechanisms have progressively become clearer but its epigenetic mechanisms remain unclear. - Source: PubMed
Publication date: 2026/02/24
Yu YihongTang HaitaoLi NanGe HaitaoWu JieGu Harvest F - - Source: PubMed
Rekhi BharatKavuncuoglu AltanDin Nasir UdRastogi SameerAbdelsatir AliStoehr RobertAgaimy AbbasKosemehmetoglu Kemal - BCOR-rearranged sarcomas constitute ultra-rare tumors. Among these, ZC3H7A/B::BCOR sarcomas are less common and are primarily reported as a subset of high-grade endometrial stromal sarcomas, as well as in the spectrum of malignant ossifying fibromyxoid tumors (OFMTs). Herein, we present the clinicopathological, immunohistochemical, and molecular profiles of seven soft tissue tumors exhibiting ZC3H7A/B::BCOR fusions. The patient's age ranged from 13 to 65 years (median = 38). Locations were neck (2) and one case each in the paraspinal region, scalp, gluteal region, chest wall, and thigh. Histologically, the tumors were composed of round to polygonal or spindle-shaped cells with a variable amount of fibromyxoid stroma, lacking bone shell or ossification, leading to a range of initial differential diagnoses. Immunohistochemically, the tumor cells were positive for S100 (5/6), cyclin D1 (2/3), SATB2 (2/3), BCOR (2/4), and TLE1 (1/3) while negative for MUC4 (0/6), keratin (0/5), EMA (0/4), desmin (0/6), CD34 (0/6), SMA (0/5), SOX10 (0/5), and melanoma cocktail (0/2). Targeted RNA sequencing revealed ZC3H7B::BCOR fusions in six tumors (four with ZC3H7Bex10::BCORex6 and one each ZC3H7Bex12::BCORex7 and ZC3H7Bex12::BCORex6). One tumor revealed a ZC3H7Aex10::BCORex6 fusion. All seven tumors were resected, mostly with clear margins (5/7), including two patients who received adjuvant therapy. Three of four patients with available follow-up (mean = 45 months) died of disease, while one patient was alive with multiple bone metastases. This series comprises seven additional ZC3H7A/B::BCOR soft tissue sarcomas associated with aggressive clinical outcomes. Whether this aggressive sarcoma represents a molecular subtype of malignant OFMT or a genetic variant of BCOR-rearranged sarcomas remains to be further verified. - Source: PubMed
Publication date: 2025/07/24
Rekhi BharatKavuncuoglu AltanDin Nasir UdRastogi SameerAbdelsatir AliStoehr RobertAgaimy AbbasKosemehmetoglu Kemal - -kinase-activating gene rearrangements occur in approximately 1-2% of non-small-cell lung carcinomas (NSCLCs). Their reliable detection requires next-generation sequencing (NGS), while conventional methods, such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) or variant-specific PCR, have significant limitations. We developed an assay that compares the level of RNA transcripts corresponding to 5'- and 3'-end portions of the gene; this test relies on the fact that translocations result in the upregulation of the kinase domain of the gene and, therefore, the 5'/3'-end expression imbalance. The present study included 16,106 consecutive NSCLC patients, 14,449 (89.7%) of whom passed cDNA quality control. The 5'/3'-end unbalanced expression was observed in 184 (1.3%) tumors, 169 of which had a sufficient amount of material for the identification of translocation variants. Variant-specific PCR revealed rearrangements in 155/169 (91.7%) tumors. RNA quality was sufficient for RNA-based NGS in 10 cases, 8 of which carried exceptionally rare or novel ( and ) translocations. We also applied variant-specific PCR for eight common rearrangements in 4680 tumors, which emerged negative upon the 5'/3'-end unbalanced expression test; 33 (0.7%) of these NSCLCs showed fusion. While the combination of the analysis of 5'/3'-end expression imbalance and variant-specific PCR allowed identification of translocations in approximately 2% of consecutive NSCLCs, this estimate approached 120/2361 (5.1%) in /////-negative carcinomas. -rearranged tumors obtained from females, but not males, had a decreased level of expression of thymidylate synthase ( < 0.00001), which is a known predictive marker of the efficacy of pemetrexed. The results of our study provide a viable alternative for testing in facilities that do not have access to NGS due to cost or technical limitations. - Source: PubMed
Publication date: 2023/06/23
Tiurin Vladislav IPreobrazhenskaya Elena VMitiushkina Natalia VRomanko Aleksandr AAnuskina Aleksandra AMulkidjan Rimma SSaitova Evgeniya SKrivosheyeva Elena AKharitonova Elena DShevyakov Mikhail PTryakin Ilya AAleksakhina Svetlana NVenina Aigul RSokolova Tatiana NMartianov Aleksandr SShestakova Anna DIvantsov Alexandr OIyevleva Aglaya GImyanitov Evgeny N - Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant cancers with more than 94% mortality rate mainly due to the widespread metastases. To find out the somatically mutated genes related to the metastasis of PDAC, we analyzed the matched tumor and normal tissue samples from a patient diagnosed with liver metastatic PDAC using intensive exome capture-sequencing analysis (> 170× coverage). Searching for the somatic mutations that drive the clonal expansion of metastasis, we identified 12 genes with higher allele frequencies (AFs) of functional mutations in the metastatic tumor, including known genes KRAS and TP53 for metastasis. Of the 10 candidate genes, 6 (ADRB1, DCLK1, KCNH2, NOP14, SIGLEC1, and ZC3H7A), together with KRAS and TP53, were clustered into a single network (p value = 1 × 10(-22)) that is related to cancer development. Moreover, these candidate genes showed abnormal expression in PDAC tissues and functional impacts on the migration, proliferation, and colony formation abilities of pancreatic cancer cell lines. Furthermore, through digital PCR analysis, we revealed potential genomic mechanisms for the KRAS and TP53 mutations in the metastatic tumor. Taken together, our study shows the possibility for such personalized genomic profiling to provide new biological insight into the metastasis of PDAC. - Source: PubMed
Publication date: 2012/08/01
Zhou BinIrwanto AstridGuo Yun-MiaoBei Jin-XinWu QiaoChen GeZhang Tai-PingLei Jin-JvFeng Qi-ShengChen Li-ZhenLiu JianjunZhao Yu-Pei